Dare Bioscience

Dare Bioscience Share Buybacks

The Share Buybacks of Dare Bioscience (DARE) as of Nov 14, 2026 is 24.76 M USD. In the previous year, Share Buybacks was 5.15 M USD — a change of 380.68% (higher).

Share Buybacks

24.76 MUSD

YoY

380.68%

Last updated:

Share Buybacks of Dare Bioscience is 2020 24.76 M USD. Share Buybacks of Dare Bioscience was 2019 5.15 M USD. It decreases by 380.68% higher compared to the previous year.

The Dare Bioscience Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2014
60.00 M USD
Jan 1, 2015
2.63 M USD
Jan 1, 2016
918,000.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
10.11 M USD
Jan 1, 2019
5.15 M USD
Jan 1, 2020
24.76 M USD
The Dare Bioscience Share Buybacks history
YEARShare BuybacksYoY
24.76 MUSD+380.68%
5.15 MUSD-49.05%
10.11 MUSD—
0.00USD-100.00%
918,000.00USD-65.07%
2.63 MUSD-95.62%
60.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Share Buybacks of Dare Bioscience is 24.76 M USD in 2020.

Share Buybacks of Dare Bioscience changed from 5.15 M USD to 24.76 M USD, representing a 380.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dare Bioscience

All Key Metrics — Dare Bioscience